Suppr超能文献

扶正降黏胶囊改善冠心病患者血栓前状态相关因素的临床研究

[Clinical study of fuzheng jiangnian capsule in improving pre-thrombosis correlated factors in patients with coronary heart disease].

作者信息

Li Lu-Yang, Ren Guo-Hua, Liu Xiang-Hong

机构信息

Hospital, Shandong University, Jinan.

出版信息

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005 Aug;25(8):691-5.

Abstract

OBJECTIVE

To explore the effect of Fuzheng Jiangnian Capsule (FZJN) on the pre-thrombosis correlated factors in patients with coronary heart disease (CHD).

METHODS

Ninety patients with CHD complicated with blood hyperviscosity syndrome were treated with conventional treatment and randomly divided into three groups by the additional treatment, i. e. the FZJN group (FZJN, a preparation with action of invigorating Pi, supplementing Shen, and activating blood circulation), the CSDP group [Compound Salviae droplet pill, CSDP) with the action of activating blood circulation to remove blood stasis) and the aspirin (ASP) group, 30 patients in each group. After two months of treatment, clinical efficacy, the levels of endothelin (ET), nitric oxide (NO), coagulation factor I (Fib), D-dimer (DD), thrombocytic granule membranous glucoprotein (CD62p), superoxide dismutase (SOD), high- and low-density lipoprotein-cholesterol (HDL-C, LDL-C) in patients before and after treatment were observed and compared with those in the healthy control group.

RESULTS

Compared with the healthy control group, the levels of Fib, DD, ET, CD62p were significantly higher, NO and SOD significantly lower (P<0.05, P<0.01) in all the patients with CHD. Compared with the same group before treatment, the levels of Fib, DD, ET, CD62p, LDL-C in the FZJN group lowered significantly, while NO and SOD raised significantly (P <0.05, P <0.01). ET and CD62p in the CSDP group lowered significantly, while SOD raised significantly (P < 0.05), CD62p in the ASP group lowered significantly (P < 0.05). No statistical difference was found in comparison of DD or ET, though certain improvement was shown. The total effective rate in relieving TCM syndromes and angina pectoris, and the decrease or stop rate of nitrate esters medication were superior in FZJN group to those in the CSDP group and the ASP group, respectively (P <0.05). The rate of electrocardiogram improvement in the FZJN and CSDP group was superior to that in the ASP group (P< 0.05).

CONCLUSION

Increase of Fib, DD, ET, CD62p, and decrease of NO and SOD levels were found in patients with CHD in prethrombosis stage. Compared with ASP, compound Chinese medicinal herbs can act on the prethrombosis manner of CHD patients through multi-paths, multi-links. FZJN showed better efficacy in improving correlated blood molecule markers and clinical syndromes than CSDP, suggesting that the possible mechanism of FZJN might be related to its actions in dilating blood vessels, improving microcirculation, alleviating endothelial cell damage, inhibiting activity of blood platelet, regulating coagulation-fibrolysis balance, improving metabolism of free radicals as well as lowering the level of LDL-C.

摘要

目的

探讨扶正降黏胶囊(FZJN)对冠心病(CHD)患者血栓前状态相关因子的影响。

方法

90例冠心病合并血液高黏滞综合征患者采用常规治疗,并根据加用的治疗药物随机分为3组,即FZJN组(FZJN,具有健脾、补肾、活血作用的制剂)、复方丹参滴丸(CSDP)组(具有活血化瘀作用)和阿司匹林(ASP)组,每组30例。治疗2个月后,观察患者治疗前后的临床疗效、内皮素(ET)、一氧化氮(NO)、凝血因子I(Fib)、D-二聚体(DD)、血小板颗粒膜糖蛋白(CD62p)、超氧化物歧化酶(SOD)、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇(HDL-C、LDL-C)水平,并与健康对照组进行比较。

结果

与健康对照组相比,所有冠心病患者的Fib、DD、ET、CD62p水平显著升高,NO和SOD水平显著降低(P<0.05,P<0.01)。与治疗前同组相比,FZJN组的Fib、DD、ET、CD62p、LDL-C水平显著降低,而NO和SOD水平显著升高(P<0.05,P<0.01)。CSDP组的ET和CD62p水平显著降低,SOD水平显著升高(P<0.05),ASP组的CD62p水平显著降低(P<0.05)。DD或ET虽有一定改善,但比较差异无统计学意义。FZJN组在缓解中医证候和心绞痛方面的总有效率,以及硝酸酯类药物的减停率分别优于CSDP组和ASP组(P<0.05)。FZJN组和CSDP组的心电图改善率优于ASP组(P<0.05)。

结论

冠心病患者血栓前状态存在Fib、DD、ET、CD62p升高,NO和SOD水平降低的情况。与ASP相比,复方中药可通过多途径、多环节作用于冠心病患者的血栓前状态。FZJN在改善相关血液分子标志物和临床证候方面的疗效优于CSDP,提示FZJN的作用机制可能与其扩张血管、改善微循环、减轻内皮细胞损伤、抑制血小板活性、调节凝血-纤溶平衡、改善自由基代谢以及降低LDL-C水平有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验